<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553369</url>
  </required_header>
  <id_info>
    <org_study_id>14/B/18</org_study_id>
    <secondary_id>2014-A01504-43</secondary_id>
    <secondary_id>2014/82</secondary_id>
    <nct_id>NCT02553369</nct_id>
  </id_info>
  <brief_title>Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection</brief_title>
  <acronym>ChikVIH</acronym>
  <official_title>Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Center of Martinique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Center of Martinique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Late 2013, the first indigenous cases of chikungunya have been observed in the French
      Antilles. At the end of May 2014, almost all of the islands of the Caribbean were affected by
      the outbreak.

      During the large epidemic which affected the Island of La Réunion in 2005/2006, the attack
      rate was 38%. The most active period was three months.

      In this context, knowledge of the attack rate and the epidemic in the Caribbean is an
      important issue for outbreak management and modeling work.

      As the chikungunya virus had never circulated in the Caribbean, determining the
      seroconversion rate can be achieved by realizing a seroprevalence survey among the general
      population at the end of the outbreak. Another simple method is to estimate the rate in a
      cohort of patients followed regularly and whose habitat is distributed throughout the
      territory studied.

      The follow up of patients infected by the human immunodeficiency virus (HIV) in the French
      West Indies is almost exclusively performed in hospitals in department of Infectious and
      Tropical Diseases.The high prevalence of HIV and homogeneous distribution of infected
      patients on all of our territories, allow to hypothesize that the risk of transmission of
      arboviruses by exposure to mosquito bites is comparable to the general population. This
      patient cohort is well suited to study the emergence of Chikungunya in the French West Indie
      .

      Primary objective :

      To estimate the cumulative incidence at the end of the first Chikungunya outbreak in the
      French West Indies by estimating the prevalence of specific antibodies of chikungunya virus
      in a sample (randomly constituted) from patients infected by HIV and representative of the
      general population of Martinique and Guadeloupe

      Secondary objective :

      To estimate the frequency of asymptomatic infections by the chikungunya virus in the studied
      population To estimate the frequency of chronic forms of chikungunya in the studied
      population
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or not of chikungunya virus-specific immunoglobulin G antibodies (Elisa test)</measure>
    <time_frame>1 day</time_frame>
    <description>Presence or not of chikungunya virus-specific immunoglobulin G antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pain</measure>
    <time_frame>6 , 12 , 18 months after the first symptoms of chikungunya virus infection</time_frame>
    <description>Score range from 0 (No pain) to 10 (worst possible pain)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">388</enrollment>
  <condition>HIV Infections</condition>
  <condition>Chikungunya Virus Infection</condition>
  <arm_group>
    <arm_group_label>Enrolled patients</arm_group_label>
    <description>Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological sample collection</intervention_name>
    <description>A blood sample is collected during a follow up visit for HIV infection.</description>
    <arm_group_label>Enrolled patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient followed for HIV infection at the 2 investigator centers.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt; 18 years old)

          -  Followed for HIV infection at the 2 investigators centers (1 located at Martinique and
             1 at Guadeloupe)

          -  resident in Martinique /Guadeloupe ( French West Indies)

          -  informed consent signed by the patient

        Exclusion Criteria:

          -  patient who lived more than 6 month in an risk area for chikungunya virus infection

          -  patient with or documented chronic rheumatism

          -  patient who has received a blood transfusion during year 2013 or patient who is
             supposed to receive a blood transfusion during the study

          -  patient who has planned to live outside French West Indies during the follow up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Guadeloupe</name>
      <address>
        <city>Pointe-à-Pitre</city>
        <state>Guadeloupe</state>
        <zip>97159</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Fort-de-France</name>
      <address>
        <city>Fort-de-France</city>
        <state>Martinique</state>
        <zip>97200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.invs.sante.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-transmission-vectorielle/Chikungunya/Donnees-epidemiologiques/Virus-Chikungunya-sur-l-ile-de-Saint-Martin-et-en-Martinique.-Point-de-situation-au-19-decembre-2013</url>
  </link>
  <reference>
    <citation>Pialoux G, Gaüzère BA, Jauréguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis. 2007 May;7(5):319-27. Review.</citation>
    <PMID>17448935</PMID>
  </reference>
  <reference>
    <citation>Farnon EC, Sejvar JJ, Staples JE. Severe disease manifestations associated with acute chikungunya virus infection. Crit Care Med. 2008 Sep;36(9):2682-3. doi: 10.1097/CCM.0b013e3181843d94.</citation>
    <PMID>18728479</PMID>
  </reference>
  <reference>
    <citation>Brouard C, Bernillon P, Quatresous I, Pillonel J, Assal A, De Valk H, Desenclos JC; workgroup &quot;Quantitative Estimation of the Risk of Blood Donation Contamination by Infectious Agents&quot;. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion. 2008 Jul;48(7):1333-41. doi: 10.1111/j.1537-2995.2008.01646.x. Epub 2008 Feb 22.</citation>
    <PMID>18298600</PMID>
  </reference>
  <reference>
    <citation>Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V, Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G. The Chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus. 2008 Oct;6(4):199-210.</citation>
    <PMID>19112735</PMID>
  </reference>
  <reference>
    <citation>Sissoko D, Moendandze A, Malvy D, Giry C, Ezzedine K, Solet JL, Pierre V. Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005-2006: a population-based survey. PLoS One. 2008 Aug 26;3(8):e3066. doi: 10.1371/journal.pone.0003066.</citation>
    <PMID>18725980</PMID>
  </reference>
  <reference>
    <citation>Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan R, Silpapojakul K. Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? Transfusion. 2013 Oct;53(10 Pt 2):2567-74. doi: 10.1111/j.1537-2995.2012.03960.x. Epub 2012 Nov 26.</citation>
    <PMID>23176378</PMID>
  </reference>
  <reference>
    <citation>Bianco C. Dengue and Chikungunya viruses in blood donations: risks to the blood supply? Transfusion. 2008 Jul;48(7):1279-81. doi: 10.1111/j.1537-2995.2008.01806.x.</citation>
    <PMID>18651905</PMID>
  </reference>
  <reference>
    <citation>Ramful D, Carbonnier M, Pasquet M, Bouhmani B, Ghazouani J, Noormahomed T, Beullier G, Attali T, Samperiz S, Fourmaintraux A, Alessandri JL. Mother-to-child transmission of Chikungunya virus infection. Pediatr Infect Dis J. 2007 Sep;26(9):811-5.</citation>
    <PMID>17721376</PMID>
  </reference>
  <reference>
    <citation>Gérardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, Lenglet Y, Touret Y, Bouveret A, Grivard P, Le Roux K, Blanc S, Schuffenecker I, Couderc T, Arenzana-Seisdedos F, Lecuit M, Robillard PY. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Réunion. PLoS Med. 2008 Mar 18;5(3):e60. doi: 10.1371/journal.pmed.0050060.</citation>
    <PMID>18351797</PMID>
  </reference>
  <reference>
    <citation>Gérardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, Michault A, de Lamballerie X, Flahault A, Favier F. Estimating Chikungunya prevalence in La Réunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect Dis. 2008 Jul 28;8:99. doi: 10.1186/1471-2334-8-99.</citation>
    <PMID>18662384</PMID>
  </reference>
  <reference>
    <citation>Van Bortel W, Dorleans F, Rosine J, Blateau A, Rousset D, Matheus S, Leparc-Goffart I, Flusin O, Prat C, Cesaire R, Najioullah F, Ardillon V, Balleydier E, Carvalho L, Lemaître A, Noel H, Servas V, Six C, Zurbaran M, Leon L, Guinard A, van den Kerkhof J, Henry M, Fanoy E, Braks M, Reimerink J, Swaan C, Georges R, Brooks L, Freedman J, Sudre B, Zeller H. Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill. 2014 Apr 3;19(13). pii: 20759. Erratum in: Euro Surveill. 2014;19(14):pii/20764. Rousset, D [added].</citation>
    <PMID>24721539</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Chikungunya Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

